Company / Cash & Equivalents
Corcept Therapeutics Incorporated Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$120.5M
FY2025
5-year range
$66.3M / $135.6M
FY2021-FY2025
Trend
-5.6%
vs FY2024
Sector context
#131 of 206
Health Care
What the data says
At $120M, Corcept Therapeutics Incorporated's cash & equivalents ranks #131 of 206 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $24M in FY2016 to $136M in FY2023.
Based on SEC 10-K filings.
$120M in FY2025 with a 5-year CAGR of +9.6%.
Declined from $136M to $120M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +22.0%
- 5-Year CAGR
- +9.6%
- 10-Year CAGR
- -
Sector benchmark
#131 of 206 in Health CareTop 64% of 206This company $120.5M Sector average $672.3M
▼
-82.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.6%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 5.6% year-over-year.
- Ranks #131 out of 206 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.5M | -5.6% |
| FY2024 | $127.7M | -5.8% |
| FY2023 | $135.6M | +104.4% |
| FY2022 | $66.3M | -14.5% |
| FY2021 | $77.6M | +1.9% |
| FY2020 | $76.2M | +143.7% |
| FY2019 | $31.3M | -39.3% |
| FY2018 | $51.5M | +65.9% |
| FY2017 | $31.1M | +28.1% |
| FY2016 | $24.2M | -40.0% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026